Most of today's major pharmaceutical companies were founded in the late 19th century. Key discoveries of the 1920s and 1930s, such as such as insulin insulin and and penicillin, became mass mass-manufactured and distributed. Umerous new drugs were developed during the 1950s and mass during the 1960s and mass-produced and produced and marketed through the 1960s.
Most of today's major pharmaceutical companies were founded in the late 19th century. Key discoveries of the 1920s and 1930s, such as such as insulin insulin and and penicillin, became mass mass-manufactured and distributed. Umerous new drugs were developed during the 1950s and mass during the 1960s and mass-produced and produced and marketed through the 1960s.
Direitos autorais:
Attribution Non-Commercial (BY-NC)
Formatos disponíveis
Baixe no formato PPS, PDF, TXT ou leia online no Scribd
Most of today's major pharmaceutical companies were founded in the late 19th century. Key discoveries of the 1920s and 1930s, such as such as insulin insulin and and penicillin, became mass mass-manufactured and distributed. Umerous new drugs were developed during the 1950s and mass during the 1960s and mass-produced and produced and marketed through the 1960s.
Direitos autorais:
Attribution Non-Commercial (BY-NC)
Formatos disponíveis
Baixe no formato PPS, PDF, TXT ou leia online no Scribd
Dr. Huma Fahim Most of today's major pharmaceutical Most of today's major pharmaceutical companies were founded in the late 19th companies were founded in the late 19th and early 20th centuries. and early 20th centuries. Key discoveries of the 1920s and 1930s, Key discoveries of the 1920s and 1930s, such as such as insulin insulin and and penicillin penicillin, became , became mass mass- -manufactured and distributed. manufactured and distributed. Switzerland, Germany and taly had Switzerland, Germany and taly had particularly strong industries, with the UK particularly strong industries, with the UK and US following suit. and US following suit. umerous new drugs were developed umerous new drugs were developed during the 1950s and mass during the 1950s and mass- -produced and produced and marketed through the 1960s. marketed through the 1960s. o o This included the first oral contraceptive, "The This included the first oral contraceptive, "The Pill, Cortisone, blood Pill, Cortisone, blood- -pressure drugs and pressure drugs and other heart medications. MAO nhibitors, other heart medications. MAO nhibitors, chlorpromazine (Thorazine), Haldol chlorpromazine (Thorazine), Haldol (Haloperidol) and the tranquilizers ushered in (Haloperidol) and the tranquilizers ushered in the age of psychiatric medication. the age of psychiatric medication. o o Valium (diazepam), discovered in 1960, was Valium (diazepam), discovered in 1960, was marketed from 1963 and rapidly became the marketed from 1963 and rapidly became the most prescribed drug in history, prior to most prescribed drug in history, prior to controversy over dependency and habituation controversy over dependency and habituation Drug Discovery Drug Discovery Drug discovery Drug discovery is the process by which is the process by which potential drugs are discovered or potential drugs are discovered or designed. designed. n the past most drugs have been discovered n the past most drugs have been discovered either by isolating the active ingredient from either by isolating the active ingredient from traditional remedies or by serendipitous traditional remedies or by serendipitous discovery. discovery. A great deal of early A great deal of early- -stage drug discovery has stage drug discovery has traditionally been carried out by universities traditionally been carried out by universities and research institutions. and research institutions. Objectives of Drug Development Objectives of Drug Development Drug deveIopment Drug deveIopment refers to activities undertaken after a refers to activities undertaken after a compound is identified as a potential drug in order to compound is identified as a potential drug in order to establish its suitability as a medication. establish its suitability as a medication. Objectives of drug development are to determine appropriate Objectives of drug development are to determine appropriate Formulation Formulation and and Dosing, Dosing, as well as to establish as well as to establish safety. safety. Research in these areas generally includes a combination of Research in these areas generally includes a combination of in vitro in vitro studies, studies, in vivo in vivo studies, and clinical trials. studies, and clinical trials. Often, large multinational corporations exhibit vertical integration, Often, large multinational corporations exhibit vertical integration, participating in a broad range of drug discovery and development, participating in a broad range of drug discovery and development, manufacturing and quality control, marketing, sales, and distribution. manufacturing and quality control, marketing, sales, and distribution. Smaller organizations, on the other hand, often focus on a specific Smaller organizations, on the other hand, often focus on a specific aspect such as discovering drug candidates or developing formulations. aspect such as discovering drug candidates or developing formulations. Often, collaborative agreements between research organizations and Often, collaborative agreements between research organizations and large pharmaceutical companies are formed to explore the potential of large pharmaceutical companies are formed to explore the potential of new drug substances. new drug substances. o o Attempts were made to increase regulation and to limit Attempts were made to increase regulation and to limit financial links between pharmaceutical companies and financial links between pharmaceutical companies and prescribing physicians, including by the relatively new prescribing physicians, including by the relatively new US US FDA FDA. . o o Such calls increased in the 1960s after the Such calls increased in the 1960s after the thalidomide thalidomide tragedy came to light, in which the use of a tragedy came to light, in which the use of a new tranquilizer in pregnant women caused severe birth new tranquilizer in pregnant women caused severe birth defects. defects. o o n 1964, the World Medical Association issued its n 1964, the World Medical Association issued its Declaration of Helsinki, which set standards for clinical Declaration of Helsinki, which set standards for clinical research and demanded that subjects give their informed research and demanded that subjects give their informed consent before enrolling in an experiment. consent before enrolling in an experiment. o o Phamaceutical companies became required to prove Phamaceutical companies became required to prove efficacy efficacy in clinical trials before marketing drugs. in clinical trials before marketing drugs. Aspects of clinical development Aspects of clinical development Scientific medical aspect Scientific medical aspect How to prove efficacy and safety of the new How to prove efficacy and safety of the new substance substance Regulatory aspect Regulatory aspect How to fulfill all relevant regulatory requirements How to fulfill all relevant regulatory requirements Organizational aspect Organizational aspect How to develop cost and time effective development How to develop cost and time effective development What is GCP? What is GCP? An international ethical and quality An international ethical and quality standard for the designing, conducting, standard for the designing, conducting, recording and reporting trials that involve recording and reporting trials that involve the participation of human subjects the participation of human subjects (CH definition) (CH definition) Four columns of GCP Four columns of GCP Protection of the rights and of the welfare of the subjects Protection of the rights and of the welfare of the subjects and ensurance of high degree of ethical standards and ensurance of high degree of ethical standards (ethics comm.) (ethics comm.) High scientific and performance quality in planning, High scientific and performance quality in planning, conduct and evaluation of clinical trials (ethical basis conduct and evaluation of clinical trials (ethical basis includes scientific rationale: statistics/sufficiently high includes scientific rationale: statistics/sufficiently high patient numbers/comparisons) patient numbers/comparisons) Comprehensive and verifiable documentation of the trial Comprehensive and verifiable documentation of the trial performance (CRFs, monitoring, SDV source data performance (CRFs, monitoring, SDV source data verification) verification) Definition of responsibilities and functions f the parties Definition of responsibilities and functions f the parties involved in clinical trials. involved in clinical trials. (legal considerations: For all interventional studies, (legal considerations: For all interventional studies, regardless of the phase, GCP is applicable regardless of the phase, GCP is applicable Drug development Drug development Preclinical toxicology D investigational new drug application Phase safety and dosage Phase evaluate effect side effect Phase Verify effect, monitor side effects DA new drug application Approval Years 0 20 10 PMS, SS, Phase V Phase 0 Phase 0 Phase 0 is a recent designation for Phase 0 is a recent designation for exploratory exploratory Conducted in accordance with FDA Conducted in accordance with FDA guidelines guidelines Sub therapeutic dose of the study drug is Sub therapeutic dose of the study drug is administered in small number of subjects administered in small number of subjects to gather preliminary data on PK & PD to gather preliminary data on PK & PD Phase Phase To get the sufficient information about the drug in order to justify the first To get the sufficient information about the drug in order to justify the first application in patients application in patients First application to First application to humans humans Usually healthy male Usually healthy male volunteers volunteers PK: absorption, PK: absorption, distribution, distribution, metabolism, excretion metabolism, excretion PD: effects on human PD: effects on human body body Bioavailability Bioavailability Dose finding Dose finding (tolerability, safety) (tolerability, safety) Food interaction Food interaction Comparison of Comparison of formulations, choice formulations, choice of route application of route application Total number of Total number of subjects: 20 subjects: 20- -100 100 Phase Phase To show effect on the disease or even prove efficacy and relative safety in To show effect on the disease or even prove efficacy and relative safety in highly selected patients highly selected patients First application to First application to patients suffering patients suffering from the disease from the disease Limited number of Limited number of patients and trial sites patients and trial sites Limited duration Limited duration Many inclusion Many inclusion exclusion criteria exclusion criteria Efficacy and short Efficacy and short term safety term safety Placebo controlled Placebo controlled trial when possible trial when possible Total number of Total number of patients: 150 patients: 150- -400 400 Phase a, to assess Phase a, to assess dosing requirements dosing requirements Phase b, to study Phase b, to study efficacy efficacy Phase Phase To get To get sufficient efficacy and safety data for marketing approval sufficient efficacy and safety data for marketing approval Treatment under real life Treatment under real life conditions: conditions: Fewer exclusion criteria Fewer exclusion criteria Confirmation of Confirmation of therapeutic benefit on a therapeutic benefit on a broad level broad level Preferably randomized Preferably randomized standard therapy standard therapy controlled, double blind, controlled, double blind, multicenter and multicenter and multinational trials multinational trials Clarification of crucial Clarification of crucial questions: questions: Short and long term Short and long term efficacy and safety efficacy and safety Efficacy and safety in Efficacy and safety in special populations special populations dentification of dentification of contraindications contraindications dentification of drug dentification of drug interactions interactions Total o. : 600 Total o. : 600- -3000 3000 Phase V Phase V To obtain extended knowledge about the new compound To obtain extended knowledge about the new compound Trials after market approval with in the Trials after market approval with in the approved indication approved indication Collection of additional safety data Collection of additional safety data Detection of non frequent side effects Detection of non frequent side effects Comparisons with new drugs introduced to Comparisons with new drugs introduced to the market the market Research on questions not yet answered Research on questions not yet answered by Phase by Phase - - Total number of subjects 1000 Total number of subjects 1000- -10,000 10,000 Post Marketing Surveillance PMS Post Marketing Surveillance PMS To enlarge safety and tolerance data base and confirm trial data in To enlarge safety and tolerance data base and confirm trial data in clinical practice clinical practice on interventional trial on interventional trial Pure observation Pure observation Does not interfere with clinical practice Does not interfere with clinical practice o trial related risks for patients o trial related risks for patients Large patient number Large patient number Trends in ew Drug Development Trends in ew Drug Development Pipelines* by Therapeutic Class Pipelines* by Therapeutic Class Trends in ew Drug Development Trends in ew Drug Development Pipelines* by Therapeutic Class Pipelines* by Therapeutic Class .8% 20.5% .3% 21.9% 1.3% 13.7% 6.5% 27.2% 8.3% 19.6% 9.1% 11.6% 9.1% 20.2% 10.7% 20.6% 8.7% 7.9% 0% 30% Respiratory Oncology/Immunologic GI/Metabolism CNS Cardiovascular Antiinfective !ercent of !hase I !ipeIine 1993-97 1998-02 2003-05 Source: Tufts CSDD Impact Report, 8(3): May/June 2006 ` Ten largest pharmaceutical firms Approval Success Rates for Approval Success Rates for CEs Also Vary by Therapeutic CEs Also Vary by Therapeutic Class Class Approval Success Rates for Approval Success Rates for CEs Also Vary by Therapeutic CEs Also Vary by Therapeutic Class Class 0.9% .% .2% 9.9% 27.2% 0.% 0 5 Approval Success Rate GI/Metabolism CNS Cardiovascular Respiratory Oncology/Immunology Antiinfective Source: Tufts CSDD Impact Report, 8(3): May/June 2006 Clinical and Approval Times Vary Clinical and Approval Times Vary Across Therapeutic Classes, Across Therapeutic Classes, 2002 2002- -04 04 Clinical and Approval Times Vary Clinical and Approval Times Vary Across Therapeutic Classes, Across Therapeutic Classes, 2002 2002- -04 04 .8 . .2 2.8 .6 .9 6.3 0.6 6.3 .3 6.6 .9 9.0 0.8 0. .7 0 1 ears Cardiovascular Anesthetic/Analgesic Gastrointestinal AIDS Antivirals Endocrine Antiinfectives Antineoplastic Neuropharmacologic Clinical Phase Approval Phase 2. 7.6 8. 7. 8.0 6.3 9.8 Source: Tufts CSDD, 2006 6.9 "uestions? "uestions? Drug deveIopment Drug deveIopment Drug deveIopment Drug deveIopment or or precIinicaI deveIopment precIinicaI deveIopment is defined in many pharmaceutical is defined in many pharmaceutical companies as the process of taking a new chemical lead through the stages companies as the process of taking a new chemical lead through the stages necessary to allow it to be tested in human necessary to allow it to be tested in human clinical trials clinical trials, although a broader definition , although a broader definition would encompass the entire process of drug discovery and clinical testing of novel would encompass the entire process of drug discovery and clinical testing of novel drug candidates. drug candidates. ontents ontents hide] hide] edit edit] New chemicaI entity (N deveIopment ] New chemicaI entity (N deveIopment ew chemical entities ew chemical entities ( (Ns Ns) are compounds which emerge from the process of ) are compounds which emerge from the process of drug discovery drug discovery. These will have promising activity against a particular biological target . These will have promising activity against a particular biological target thought to be important in disease, however little will be known about the safety, thought to be important in disease, however little will be known about the safety, toxicity toxicity, , pharmacokinetics pharmacokinetics and and metabolism metabolism of this CE in humans. t is the function of of this CE in humans. t is the function of drug development to assess all of these parameters prior to human clinical trials. A drug development to assess all of these parameters prior to human clinical trials. A further major objective of drug development is to make a recommendation of the further major objective of drug development is to make a recommendation of the dose and schedule to be used the first time an CE is used in a human clinical trial dose and schedule to be used the first time an CE is used in a human clinical trial (" ("first first- -in in- -man man", FM). ", FM). n addition, drug development is required to establish the physicochemical properties n addition, drug development is required to establish the physicochemical properties of the CE: its chemical makeup, stability, solubility. The process by which the of the CE: its chemical makeup, stability, solubility. The process by which the chemical is made will be optimized so that from being made at the bench on a chemical is made will be optimized so that from being made at the bench on a milligram milligram scale by a scale by a synthetic chemist synthetic chemist, it can be manufactured on the , it can be manufactured on the kilogram kilogram and and then on the then on the ton ton scale. t will be further examined for its suitability to be made into scale. t will be further examined for its suitability to be made into capsules capsules, , tablets tablets, aeresol, intramuscular injectable, subcuteneous injectable, or , aeresol, intramuscular injectable, subcuteneous injectable, or intravenous intravenous formulations formulations. Together these processes are known in preclinical . Together these processes are known in preclinical development as development as : Chemistry, Manufacturing and Control. : Chemistry, Manufacturing and Control. Many aspects of drug development are focused on satisfying the Many aspects of drug development are focused on satisfying the regulatory regulatory